Lacosamide serum concentrations in adult patients with epilepsy: The influence of gender, age, dose, and concomitant antiepileptic drugs

Therapeutic Drug Monitoring

Volumn 36, Issue 4, 2014, Pages 494-498

  Markoula, Sofia ^a,b,c   Teotonio, Rute ^a,b,c   Ratnaraj, Neville ^a,b   Duncan, John S ^a,b,c   Sander, Josemir W ^a,b,c   Patsalos, Philip N ^a,b,c  

^a EPILEPSY SOCIETY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Antiepileptic drugs; Enzyme inducing antiepileptic drugs; Lacosamide; Pharmacokinetic interactions; Serum lacosamide concentration; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; HARKOSERIDE; PHENYTOIN; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; LACOSAMIDE; VALPROIC ACID;

ADULT; AGE; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; BLOOD; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; ENZYME INDUCTION; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SEIZURES;

ACETAMIDES; ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; RETROSPECTIVE STUDIES; SEIZURES; VALPROIC ACID;

EID: 84904553623     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000051     Document Type: Article

References (35)

1. Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother. 2012;13:699-715.
2. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308-1317.
3. Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother. 2010;11:1595-1602.
4. Biton V. Lacosamide for the treatment of partial-onset seizures. Expert Rev Neurother. 2012;12:645-655.
5. Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics. 2007; 4:145-148.
6. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the eighth Eilat conference (Eilat VIII). Epilepsy Res. 2007;73:1-52.
7. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50:459-471.
8. Thomas D, Scharfenecker U, Schiltmeyer B, et al. Low potential for drug-drug interaction of lacosamide. Epilepsia. 2006;47(suppl 4):200.
9. Cawello W, Boekens H, Bonn R. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet. 2010;11:1595-1602.
10. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (Eilat VII). Epilepsy Res. 2004;61:1-48.
11. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
12. Patsalos PN. Antiepileptic Drug Interactions. A Clinical Guide. 2nd ed. London, United Kingdom: Springer; 2013.
13. Johannessen Landmark C, Patsalos PN. Methodologies used to identify and characterize interactions among antiepileptic drugs. Expert Rev Clin Pharmacol. 2012;5:281-292.
14. Nickel B, Zisowsky J, Cawello W, et al. Population pharmacokinetics of LCM in subjects with partial-onset seizures: results from two phase III trials. J Clin Pharmacol. 2008:48:1129.
15. Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52: 1739-1748.
16. Contin M, Albani F, Riva R, et al. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013;35:849-852.
17. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010; 51:958-967.
18. Beydoun A, D'Souza J, Hebert D, et al. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partialonset seizures. Expert Rev Neurother. 2009;9:33-42.
19. Ben-Menachem E. Lacosamide. An investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc). 2008;44: 35-40.
20. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443-453.
21. Greenaway C, Ratnaraj N, Sander JW, et al. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther Drug Monit. 2010;32:448-452.
22. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
23. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49:1239-1276.
24. Krasowski M. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel). 2010;3:1909-1935.
25. Brandt C, May TW. Therapeutic drug monitoring of newer antiepileptic drugs. J Lab Med. 2011;35:161-169.
26. Battino D, Croci D, Granata T, et al. Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther Drug Monit. 1997;19:620-627.
27. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002;24:366-374.
28. May TW, Rambeck B, Neb R, et al. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2007;29:789-794.
29. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit. 2005;27:199-204.
30. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 2007;48: 1351-1359.
31. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13:21-42.
32. Cawello W, Rosenkranz B, Schmid B, et al. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54:530-536.
33. Sattler A, Schaefer M, May TW, et al. Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions- first clinical experience. Epilepsy Res. 2011;95:207-212.
34. Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia. 2004;45(suppl 7):31.
35. Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627-645.